Roche to Complete $1.5 Billion Acquisition of Poseida Therapeutics Roche said it planned to complete its purchase of U.S. biopharmaceutical company Poseida Therapeutics (NASDAQ: PSTX), a specialist in complex immune cell

Roche to Complete $1.5 Billion Acquisition of Poseida Therapeutics

abbonews.com/healthcare/r...

#PoseidaTherapeutics #Wallstreet #NYSE #NASDAQ #Stocks #StockNews #StockMarketNews #news #newsalert #BusinessNews

#PSTX worth buying? #poseidatherapeutics #stocks #stockstobuy